ABCL
HealthcareAbCellera Biologics Inc. · Biotechnology · $2B
What is AbCellera Biologics Inc.?
AbCellera Biologics is a Canadian biotech company built around an AI-powered antibody discovery platform. It partners with pharmaceutical companies to find antibody drug candidates from natural immune system data.
AbCellera licenses its full-stack discovery platform to biotech and pharma partners, generating revenue through research fees and downstream royalties. The platform screens natural immune databases to identify antibody candidates, then supports partners through development. A notable collaboration exists with Eli Lilly and Company.
Incorporated in 2012 and headquartered in Vancouver, Canada.
- AI-powered antibody discovery platform
- Partner discovery programs and research collaborations
- Royalty and licensing agreements
Is ABCL a Good Stock to Buy?
UQS Score rates ABCL as Poor overall.
The Risk pillar stands out as the relative bright spot, suggesting the balance sheet carries less immediate financial danger than the overall score might imply.
Quality, Moat, and Growth all register as Weak, while Valuation reads as Elevated — a combination that raises meaningful questions about near-term investment merit.
See the exact pillar breakdown and full financial metrics by signing up for a Pro account at UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does ABCL pay dividends?
No — AbCellera Biologics Inc. does not currently pay a dividend.
ABCL does not pay a dividend. Early-stage biotech companies like AbCellera typically reinvest all available capital into platform development, discovery programs, and partnership expansion rather than returning cash to shareholders.
When does ABCL report earnings?
AbCellera Biologics reports earnings on a quarterly cadence, typical for US-listed equities.
Revenue is closely tied to partner activity and milestone payments, which can create variability quarter to quarter. The growth profile currently registers as Weak relative to sector peers.
For the most recent quarter's results, visit AbCellera's investor relations page directly.
ABCL Price History
-85.1% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in AbCellera Biologics Inc.?
Based on AbCellera Biologics Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does AbCellera Biologics do?
AbCellera operates an AI-powered antibody discovery platform that searches natural immune system databases to identify drug candidates. It partners with pharmaceutical and biotech companies, supporting programs from initial discovery through development under research and licensing agreements.
Does ABCL pay dividends?
No, ABCL does not currently pay a dividend. As an early-stage biotech, the company directs capital toward platform development and growing its partner discovery programs rather than distributing cash to shareholders.
When does ABCL report earnings?
AbCellera reports on a standard quarterly schedule. For exact dates and the latest results, check the investor relations section of the company's official website.
Is ABCL a good stock to buy?
The UQS Score rates ABCL as Poor, with Weak readings across Quality, Moat, and Growth, and an Elevated Valuation. The Risk pillar is the relative standout. Investors should weigh these factors carefully against their own risk tolerance.
Is ABCL overvalued?
The UQS Valuation pillar for ABCL is rated Elevated, suggesting the current market price may not be well-supported by the company's underlying fundamentals relative to sector peers. Pro members can view the full valuation metrics.
What is ABCL's market cap bracket?
ABCL is classified as a small-cap stock. This places it in a segment of the market that can carry higher volatility and liquidity risk compared to large- or mega-cap healthcare companies.
Is ABCL a long-term quality investment?
As a long-term quality indicator, the UQS Score currently rates ABCL as Poor. Weak Moat and Quality scores suggest the company has not yet established the durable competitive advantages typically associated with long-term compounders in the healthcare sector.
What sector does ABCL belong to?
AbCellera Biologics operates in the Healthcare sector, specifically within the biotechnology space. It focuses on antibody drug discovery technology rather than direct drug development or commercialization.
Unlock Full ABCL Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS pillar scores across all five dimensions
- ✓Access detailed financial metrics and trend data
- ✓Compare ABCL against sector peers on a normalized basis
- ✓Get the complete analyst-style quality breakdown in one place
Pro Analysis
ABCL — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 14, 2026 | 25.9 | 1.3 | 28.0 | 31.4 | 82.4 | 0.0 | -0.4 |
| May 12, 2026 | 26.3 | 2.5 | 28.0 | 31.4 | 82.4 | 0.0 | +1.2 |
| May 11, 2026 | 25.1 | 2.5 | 28.0 | 31.4 | 74.6 | 0.0 | +0.6 |
| May 10, 2026 | 24.5 | 0.0 | 28.0 | 31.4 | 74.6 | 0.0 | -0.6 |
| Apr 2, 2026 | 25.1 | 2.5 | 28.0 | 31.4 | 74.6 | 0.0 | — |
ABCL — Pillar Breakdown
Quality
— 1.3/100 (25%)AbCellera Biologics Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 31.4/100 (20%)AbCellera Biologics Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 82.4/100 (15%)AbCellera Biologics Inc. carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)AbCellera Biologics Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 28/100 (25%)AbCellera Biologics Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for ABCL.
Score Composition
Financial Data
More Stock Analysis
How is the ABCL UQS Score Calculated?
The UQS (Unified Quality Score) for AbCellera Biologics Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses AbCellera Biologics Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether AbCellera Biologics Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.